We are evaluating an improved treatment for this debilitating condition
Leprosy, also known as Hansen’s Disease, is a chronic infectious disease which may cause skin lesions and nerve damage. It is caused by slow-growing Mycobacterium leprae bacteria.
Around 30 to 50 per cent of leprosy patients develop leprosy type 2 reactions (also known as erythema nodosum leprosum). This condition is an immune-mediated and severe complication of leprosy, which can affect people with active leprosy infection, as well as those that have been effectively cured with multidrug therapy, even many years later. Patients usually present with painful nodules, often distributed between existing lesions, and moderate to high fever. Leprosy and leprosy reactions patients have been stigmatized and discriminated against since time immemorial, and at least 17 countries still allow discrimination based on this disease (WHO).
208,619
208,619 new cases of leprosy were registered in 2018 (WHO)
127
127 countries: leprosy is found in, with the largest number of cases in India, followed by Indonesia and Brazil
Source:
World Health Organization. Weekly epidemiological record. Global leprosy (Hansen disease) update, 2019: time to step-up prevention initiatives. 2020. https://apps.who.int/iris/bitstream/handle/10665/334140/ WER9536-eng-fre.pdf?sequence=1&isAllowed=y&ua=1
World Health Organization. 2019 WHO Leprosy fact sheet. https://www.who.int/newsroom/fact-sheets/detail/leprosy
Voorend CGN, Post EB. A Systematic Review on the Epidemiological Data of Erythema Nodosum Leprosum, a Type 2 Leprosy Reaction. PLOS Neglected Tropical Diseases. 2013 Oct 3;7(10):e2440.
30-50%
30 to 50% of leprosy patients also develop erythema nodosum leprosum, an immune-mediated and severe complication of leprosy
Leprosy type 2 reactions are currently treated mainly with corticosteroids, which are often required for extended periods of time, leading to serious adverse effects. The inflammatory responses of leprosy type 2 reactions can cause morbidity and mortality if not treated in a timely manner.
CC-11050 has completed a Phase 2a clinical trial and is about to be evaluated in a Phase 2b study in Nepal, sponsored by the Leprosy Mission and funded by Amgen, Inc.
Primarily affecting the lungs, tuberculosis remains the leading cause of infectious death worldwide.
A debilitating and disfiguring disease found in 31 African countries and beyond.
An infectious skin condition affecting more than 200 million people at any one time.
A painful and debilitating disease of the lymph system affecting over 50 million people at any one time.
A soil-transmitted infection affecting up to 100 million people, particularly children.
A chronic infectious disease which may cause skin lesions and nerve damage found in 127 countries.
Among the most common of all infections with an estimated 1.5 billion people infected worldwide.